New drug cocktail aims to reverse nerve damage in rare blood disorder
NCT ID NCT05939037
First seen May 16, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests whether adding zanubrutinib to standard rituximab therapy can improve walking and arm function in people with a rare blood condition (IgM MGUS) that causes nerve damage. About 35 adults will receive the combination for up to a year, with follow-up lasting 3 years. The goal is to see if the treatment reduces disability and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Medical Center Utrecht
Utrecht, Utrecht, 3584CX, Netherlands
Conditions
Explore the condition pages connected to this study.